Novavax Initiates Phase 2 Clinical Trial of NanoFlu™ in Older Adults
- First participants enrolled in Phase 2 clinical trial of quadrivalent NanoFlu formulations
- Top-line immunogenicity and safety data expected in the first quarter of 2019
- Phase 2 results will support meeting with the U.S. Food and Drug Administration (FDA) and Phase 3 clinical trial design
GAITHERSBURG, Md., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX) today announced the initiation of a Phase 2 dose and formulation confirmation clinical trial in older adults of NanoFlu, its nanoparticle seasonal influenza vaccine candidate.
“Initiating this Phase 2 clinical trial of NanoFlu is an important milestone for Novavax,” said Stanley C. Erck, President and Chief Executive Officer of Novavax. “With top-line results expected in the first quarter of 2019, we plan to discuss these data with the FDA at an ‘End of Phase 2’ meeting and to agree on the appropriate Phase 3 clinical trial design to support licensure via accelerated approval. We continue to believe NanoFlu is a differentiated flu vaccine capable of better addressing a global public health problem, and can thereby capture a significant share of the multi-billion-dollar seasonal influenza vaccine market.”
This randomized, observer-blinded, active-controlled trial will assess the safety and tolerability of different doses and formulations of NanoFlu, both adjuvanted with its proprietary Matrix-M™ adjuvant and unadjuvanted, as compared to two U.S.-licensed comparators. The trial will enroll approximately 1,375 healthy older adults across clinical sites in the U.S. and is designed to select a dose/formulation of NanoFlu that Novavax will bring forward into its future pivotal Phase 3 immunogenicity clinical trial.
“The dual problems of antigenic drift and antigenic changes resulting from egg-based vaccine production have, in recent years, resulted in generally poor influenza vaccine effectiveness with potentially severe medical consequences, particularly in older adults. A substantially improved seasonal influenza vaccine is a widely recognized, high-priority unmet medical need,” said Gregory Glenn, M.D., President of Research and Development of Novavax. “We look forward to evaluating NanoFlu in this trial, and subsequently moving into a pivotal Phase 3 clinical trial in the second half of 2019 with the goal of introducing a more effective flu vaccine option.”
More information about the newly initiated trial can be found at www.clinicaltrials.gov.
Previously Reported Phase 1/2 Clinical Trial Results with NanoFlu
In February 2018, Novavax reported positive top-line results from its Phase 1/2 clinical trial in older adults of a NanoFlu trivalent formulation. As compared to Fluzone HD, NanoFlu demonstrated an acceptable safety profile and short-term reactogenicity. With regard to immunogenicity, NanoFlu induced:
- Hemagglutination inhibition (HAI) immune responses that were 28% to 64% greater against the homologous and four generations of drifted wild-type A(H3N2) influenza strains;
- Higher HAI responses against the homologous A(H1N1) strain and comparable responses against the homologous B/Brisbane strain; and
- Strong neutralizing antibody responses that correlate with HAI results.
Influenza is a world-wide infectious disease that causes illness in humans with symptoms ranging from mild to life-threatening or even death. Serious illness occurs not only in susceptible populations such as infants, young children and older adults, but also in the general population largely because of infection by continuously evolving strains of influenza which can evade the existing protective antibodies in humans. An estimated one million deaths globally each year are attributed to influenza.1 Current estimates for seasonal influenza vaccine growth in the top seven markets (U.S., Japan, France, Germany, Italy, Spain and UK), show a potential increase from approximately $3.2 billion in 2015 to $5.3 billion by 2025.2
1 Resolution of the World Health Assembly (2003) WHA56.19.28
2 Influenza Vaccines Forecasts. Datamonitor (2013)
About NanoFlu™ and Matrix-M™
NanoFlu is a recombinant hemagglutinin (HA) protein nanoparticle influenza vaccine produced by Novavax in its SF9 insect cell baculovirus system. NanoFlu uses HA amino acid protein sequences that are the same as the recommended wild-type circulating virus HA sequences. NanoFlu contains Novavax’ patented saponin-based Matrix-M adjuvant, which has demonstrated a potent and well-tolerated effect by stimulating the entry of antigen-presenting cells into the injection site and enhancing antigen presentation in local lymph nodes.
About Accelerated Approval
Accelerated approval may be granted for certain biological products that have been studied for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments. Such an approval will be based on adequate and well-controlled clinical trials establishing that the biological product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit. For seasonal influenza vaccines, the hemagglutination inhibition (HAI) antibody response may be an acceptable surrogate marker of activity that is reasonably likely to predict clinical benefit. To be considered for accelerated approval, a biologics license application for a new seasonal influenza vaccine should include results from one or more well-controlled studies designed to meet immunogenicity endpoints and a commitment to conduct confirmatory post-marketing studies of clinical effectiveness in preventing influenza.
Novavax, Inc. (Nasdaq:NVAX) is a late-stage biotechnology company that drives improved health globally through the discovery and development of innovative vaccines to prevent serious respiratory diseases. ResVax, its RSV vaccine for infants via maternal immunization, is the only vaccine in a Phase 3 clinical program and is poised to help prevent the second leading cause of death in children under one year of age worldwide. Novavax is also advancing NanoFlu, its quadrivalent influenza nanoparticle vaccine, to address key factors that can lead to the poor effectiveness of currently approved flu vaccines. Novavax is a leading innovator of recombinant vaccines; its proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce a new class of highly immunogenic nanoparticles addressing urgent global health needs.
Statements herein relating to the future of Novavax and the ongoing development of its vaccine and adjuvant products are forward-looking statements. Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include those identified under the heading “Risk Factors” in the Novavax Annual Report on Form 10-K for the year ended December 31, 2017 and the Quarterly Report on Form 10-Q for the period ended June 30, 2018 as filed with the Securities and Exchange Commission (SEC). We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.
Senior Manager, Investor & Public Relations
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg saker fra GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra GlobeNewswire
TriLumina Launches the World’s First Surface-Mount Flip-Chip Back-Emitting VCSEL Array Without the Need for a Submount20.6.2019 19:00:00 CEST | Pressemelding
Game-changing “LED Killer” Device Enables Lowest Cost, Smallest, High Performance for Mobile 3D Sensing Applications and Innovative NIR Illumination Options ALBUQUERQUE, N.M., June 20, 2019 (GLOBE NEWSWIRE) -- TriLumina, the leading developer of flip-chip VCSEL(vertical-cavity surface-emitting laser) technology for 3D sensing, announces the launch of the world’s first surface-mount flip-chip back-emitting VCSEL array without the need for a submount or bond wires, which allows for lower costs and higher performance than existing designs using near-infrared light-emitting laser diodes or LEDs for 3D sensing. “We are pleased to launch this revolutionary device,” said Luke Smithwick, chief marketing officer for TriLumina. “For the first time, engineers can create extremely small, low-cost, high-performance products utilizing a NIR surface mount back-emitting VCSEL array, without the need for a large and costly submount.” Conventional VCSEL arrays are mounted on a submount and use bond wire
Constellation Brands CEO Bill Newlands Signs CEO Action for Diversity & Inclusion Pledge20.6.2019 15:00:00 CEST | Pressemelding
VICTOR, N.Y., June 20, 2019 (GLOBE NEWSWIRE) -- Constellation Brands, Inc. (NYSE: STZ and STZ.B), a leading beverage alcohol company, announced today that that Bill Newlands, president and chief executive officer, is joining CEO Action for Diversity & Inclusion™ - the largest CEO-driven business commitment to advance diversity and inclusion within the workplace. The CEO Action for Diversity & Inclusion recognizes that change often happens when there’s support at the executive level. More than 600 CEOs of the world’s leading companies and business organizations are leveraging their voices to advance diversity and inclusion in the workplace by placing individual accountability on all—leaders and employees—to create inclusive environments. “At Constellation, we work hard to foster an inclusive culture that is characterized by diversity in background and thought, and that reflects our consumers and the communities where we live and work,” said Newlands. “Signing the CEO Action for Diversit
Radient Technologies Inc. Provides Update on Progress of Cannabis and Hemp Extraction Facilities and Issues Shares for Services20.6.2019 13:30:00 CEST | Pressemelding
EDMONTON, Alberta, June 20, 2019 (GLOBE NEWSWIRE) -- Radient Technologies Inc. (“Radient” or the “Company”) (TSX Venture: RTI; OTCQX: RDDTF) is pleased to announce it has awarded the mandate for the second phase of the construction of its Edmonton III manufacturing facility to Fillmore Construction Management Inc. (“Fillmore”). Construction is well underway, with footings and foundation work having been completed, and the structural component of the building now in progress and on schedule. Fillmore was selected by Radient due to its extensive previous experience developing food processing and GMP approved manufacturing plants. Edmonton III is Radient’s expanded capacity cannabis and hemp processing line that is expected to have a total annual throughput capacity of 280,000 kg/year of cannabis, and 2,800,000 kg/year of hemp upon completion in calendar 2020. Radient completed its first commercial extraction run for Aurora Cannabis Inc. (“Aurora”) (TSX: ACB; NYSE: ACB) in May 2019 at its
TeraRecon Receives First-of-Kind FDA Determination20.6.2019 11:00:00 CEST | Pressemelding
DURHAM, N.C., June 20, 2019 (GLOBE NEWSWIRE) -- Advanced visualization and artificial intelligence (AI) technology provider, TeraRecon, today announced it has successfully completed an FDA regulatory review of its Northstar™ AI Results Explorer, for which the technology and the determination are both firsts-of-kind in the medical imaging industry. Northstar is designed to work alongside the company’s EnvoyAI™ interoperability platform which includes FDA-cleared 3rd party content listed on its EnvoyAI Exchange marketplace. The Northstar determination letter reinforces the company’s commitment to regulatory and quality standards along with transparency in the field of medical imaging artificial intelligence. The Northstar AI Results Explorer provides an engaging physician user experience which can be integrated into the clinical systems already used throughout the health enterprise. Now with full commercial availability, Northstar can provide physicians an important way to accept, reject
Appian Named A Leader in Digital Process Automation for Deep Deployments Report by Independent Research Firm19.6.2019 16:28:00 CEST | Pressemelding
RESTON, Va, June 19, 2019 (GLOBE NEWSWIRE) -- Appian (NASDAQ: APPN) today announced it has been named a leader in “The Forrester Wave™: Software For Digital Process Automation For Deep Deployments, Q2 2019” report (“DPA Deep”). In Forrester’s four market segments for rapid application development, DPA Deep platforms “excel at the high end of process complexity but may also be the right solution to meet the needs for a wide-deployment, low-code standard” in an organization. In Forrester’s evaluation, Appian tied for the top score in the Current Offering category (including criteria for user experience development tools; process and flow design; digital decisioning, and robotic process automation). Appian also received among the second-highest scores in the Strategy category (including criteria like vision and strategy, commercial model, partners and training, community, and marketplace). The report notes that “Appian is a low-code vendor that thrives in complex process environments.” Th
Seaborn Networks announces new IP & Ethernet Services for Brazil and U.S. market19.6.2019 14:30:00 CEST | Pressemelding
BOSTON, June 19, 2019 (GLOBE NEWSWIRE) -- Seaborn Networks (“Seaborn”), a leading developer-owner-operator of subsea fiber optic cable systems, today announced that it will be delivering industry leading performance with new IP Service offerings comprising of diverse Ethernet Service and IP Service solutions addressing the market’s demand for rapidly deployed and highly stable global Ethernet & IP based needs between North and South America. IP Service offerings will include IP Transit, Remote Peering, Cloud Connect and Enterprise DIA solutions. Seaborn’s IP Services are offered under a minimal commitment with the ability to utilize additional bandwidth on a pay-as-you-use basis. Seaborn’s Ethernet Service offerings include E-Line, E-LAN and E-Tree capabilities with options for protected service depending on the Class of Service (CoS) selected. Industry leading SLA’s are provided on all IP and Ethernet services. “In today’s fast paced, highly complex communications environment, busines